<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104101</url>
  </required_header>
  <id_info>
    <org_study_id>Alexandria University</org_study_id>
    <nct_id>NCT03104101</nct_id>
  </id_info>
  <brief_title>Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females</brief_title>
  <official_title>Evaluation of Transcutaneous Posterior Tibial Nerve Electro Stimulation With or Without Low Dose Trospium Chloride in the Management of Overactive Bladder in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was done to verify whether the combination of transcutaneous posterior tibial
      nerve stimulation (TPTNS) with low dose trospium chloride in the treatment of females with
      overactive bladder (OAB) would be more effective than TPTNS alone after failure of behavioral
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators randomized 30 women with OAB, in two groups: G I (15 patients) received 30
      minutes TPTNS, three times a week; GII (15 patients) received TPTNS plus Low dose trospium
      chloride (20 mg once daily); all for 8 weeks. Patients were evaluated using Overactive
      Bladder Symptom Score questionnaire (OABSS), Incontinence Impact Questionnaire-short form 7
      (IIQ-7), 3 day voiding diary and urodynamics at weeks 0 and 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2014</start_date>
  <completion_date type="Actual">March 5, 2016</completion_date>
  <primary_completion_date type="Actual">November 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>Improvement in the questionnaire scores and associated willingness of the patient to continue treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>TPTNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those who received Transcutaneous posterior tibial nerve stimulation sessions only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPTNS+Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TPTNS+Drug</intervention_name>
    <description>one tablet Trospium Chloride 20 mg once daily Plus TPTNS</description>
    <arm_group_label>TPTNS+Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TPTNS</intervention_name>
    <description>Surface adhesive electrodes placed on the skin above medial malleolus</description>
    <arm_group_label>TPTNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thirty adult female patients having OAB symptoms (wet type) and proved to have
             detrusor overactivity by urodynamics

        Exclusion Criteria:

          1. Patients having urinary tract infection or bladder outlet obstruction.

          2. Patients having neurological diseases.

          3. Patients having gynecological problems as genital infection, pelvic organ prolapse or
             genital tumors.

          4. Patients with electronic implants such as heart pacemakers.

          5. During pregnancy

          6. Patients subject to seizures
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Amr Gaber Abdulfattah Ali Abulseoud</investigator_full_name>
    <investigator_title>Urology Specialist</investigator_title>
  </responsible_party>
  <keyword>PTNS</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>TPTNS</keyword>
  <keyword>Trospium chloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trospium chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

